Dr. Emmy Verschuren received her PhD from UCL in 2003, following graduate studies with Prof. Nic Jones at the Imperial Cancer Research Fund (ICRF, now CRUK) in London, and Prof. Gerard Evan at the UCSF Comprehensive Cancer Center in San Francisco, investigating oncogenic activities of a herpesvirus cyclin. In 2003, she was awarded a Damon Runyon Fellowship for a postdoc with Dr. Peter Jackson at Stanford University, studying cell cycle control imposed by the Anaphase-Promoting Complex ubiquitin ligase inhibitor Emi1. In 2006, her host group moved to Genentech Inc. in South San Francisco, and there she applied a senescence screen to discover new tumour suppressors. In 2009, Emmy became a FIMM-EMBL International Group Leader at the Institute for Molecular Medicine Finland (FIMM), a Nordic EMBL Partnership for Molecular Medicine institute with partners in Sweden, Norway and Denmark. Since 2010, she acted as the academic coordinator of the IMI-JU public-private PREDECT consortium. She has been a European Association of Cancer Research (EACR) representative for Young Investigators since 2012. Her current FIMM team consists of seven researchers, and investigates complex murine and human lung cancer models to study disease progression, therapeutic targeting and intervention.